SYS-CON MEDIA Authors: Michael Bushong, Eric Brown, Gilad Parann-Nissany, Kevin Benedict, PR.com Newswire

News Feed Item

Active Biotech AB Interim report January - September 2012

LUND, SWEDEN -- (Marketwire) -- 11/09/12 --


· Laquinimod - Teva to initiate a new Phase III study in the US at year-end - milestone payment of USD 5 M received following a submitted application for regulatory approval in Europe - Crohn's Phase II data presented at the UEGW conference

· TASQ - biomarker data presented at the ESMO conference - Ipsen to initiate two new clinical Phase II studies: maintenance therapy for prostate cancer and a study of other types of cancer

· ANYARA - Phase III study results to be presented Q1 2013

· 57-57 - clinical trial of systemic sclerosis/scleroderma is in progress

· ISI - project proceeding as planned

· Net sales: SEK 136.4 M (231.3)

· Operating loss: SEK 168.7 M (loss 6.2)

· Loss after tax: SEK 175.1 M (loss: 1.3)

· Loss per share for the period: SEK 2.54 (loss: 0.02)

This report is also available at www.activebiotech.com

Active Biotech AB Interim report January - September 2012: http://hugin.info/1002/R/1656396/535516.pdf

This announcement is distributed by Thomson Reuters on behalf of Thomson Reuters clients. The owner of this announcement warrants that:

(i) the releases contained herein are protected by copyright and other applicable laws; and

(ii) they are solely responsible for the content, accuracy and originality of the information contained therein.

Source: Active Biotech via Thomson Reuters ONE

[HUG#1656396]

For further information, please contact:

Tomas Leanderson
President and CEO
Tel: +46 (0)46 19 20 95

Hans Kolam
CFO
Tel: +46 (0)46 19 20 44

Active Biotech AB (Corp. Reg. No. 556223-9227)
Box 724, SE-220 07 Lund
Tel: +46 (0)46 19 20 00
Fax: +46 (0)46 19 11 00

More Stories By Marketwired .

Copyright © 2009 Marketwired. All rights reserved. All the news releases provided by Marketwired are copyrighted. Any forms of copying other than an individual user's personal reference without express written permission is prohibited. Further distribution of these materials is strictly forbidden, including but not limited to, posting, emailing, faxing, archiving in a public database, redistributing via a computer network or in a printed form.